Scientific Perspectives on Fumarate Transitions in MS: A Clinical Review of MMF Data and Observations

Educational Webinar

Scientific Perspectives on Fumarate Transitions in MS: A Clinical Review of Monomethyl Fumarate (MMF) Data and Observations

Join a panel of leading MS specialists for a scientific evaluation of fumarate-based therapies in the management of Relapsing-Remitting Multiple Sclerosis (RRMS). Through a review of clinical observations and a panel discussion, this session will examine the scientific evidence surrounding the transition from dimethyl fumarate (DMF) or diroximel fumarate (DRF) to monomethyl fumarate (MMF). The panel will evaluate clinical data related to lymphocyte count monitoring and gastrointestinal tolerability profiles associated with fumarate treatment sequences.

Tuesday, June 9, 2026

11:00 am ET | 10:00 am CT | 8:00 am PT1 hourOnline via Zoom

Overview

The long-term management of RRMS necessitates a dual focus: maintaining sustained neuroprotection and mitigating treatment limiting side effects. While fumarate-based, disease-modifying therapies (DMTs) remain integral to the MS treatment landscape, clinicians frequently encounter practical barriers; specifically, lymphopenia and gastrointestinal (GI) distress which can undermine treatment adherence and patient quality of life.

Critical to therapeutic success is a nuanced understanding of how different fumarate formulations are associated with safety, tolerability, and monitoring considerations in clinical practice. This webinar will review real world evidence and case based clinical experience relating to fumarate based therapies, including discussion of lymphocyte monitoring, gastrointestinal tolerability, and pharmacologic differences reported in routine care.

In this webinar

Clinicians from Vanderbilt University Neurology Clinic will present data from a retrospective review of lymphocyte changes in MS patients transitioning between fumarate formulations.
Dr. Berkovich, a leading expert with her own private practice will lead a case-based discussion examining clinical observations of lymphocyte monitoring and gastrointestinal (GI) tolerability profiles during treatment transitions.

Meet the panelists

Dr. Harold Moses, MD

Dr. Harold Moses, MD, is an Associate Professor of Neurology at Vanderbilt University Medical Center and a clinician at the Vanderbilt Multiple Sclerosis Center. He specializes in neuroimmunology and MS, with clinical expertise spanning relapsing and progressive MS, neuromyelitis optica spectrum disorders, and related inflammatory neurologic conditions.

John Kramer, PA-C

John Kramer, PA‑C, is a certified physician assistant at the Vanderbilt Multiple Sclerosis Center with more than 20 years of experience in neuroimmunology. He is actively involved in the care of patients with neurological disorders and has contributed to numerous clinical research trials, peer‑reviewed publications, and national conference presentations.

Megan Schneider, PharmD

Megan Schneider, PharmD, is a clinical pharmacist at the Vanderbilt University Medical Center with expertise in the pharmacokinetics and clinical application of therapies for MS. She is the first author on research evaluating fumarate formulations and contributes to the interpretation of real‑world and clinical data to inform treatment optimization in MS.

Dr. Regina Berkovich, MD, PhD

Dr. Regina Berkovich, MD, PhD, is a leading neurologist and the founder of Dr. Regina Berkovich, MD, PhD, Private Practice Clinic, which specializes in the care of patients with MS. She brings extensive clinical experience in MS diagnosis and long‑term disease management, with a focus on optimizing treatment strategies to improve patient outcomes.

Clinical learning objectives

At the end of this webinar, participants will be able to:

Summarize the role of fumarate-based DMTs in the management of RRMS.
Compare safety and tolerability considerations across DMF, DRF, and MMF, with emphasis on lymphocyte count and GI tolerability.
Evaluate clinical considerations and real world experiences related to transitioning between fumarate formulations, including impacts on lymphocyte counts and gastrointestinal tolerability.

First Name^*

Last Name^*

Email Address^*

Phone

Organization^*

Job Title^*

Are there any specific questions you'd like us to address during this webinar?

I agree to the terms and conditions^*

I authorize Cycle Pharmaceuticals and its service providers to contact me regarding Cycle Pharmaceuticals’ products, services, and programs via:^* Email Text Phone

Terms and conditions

By ticking the consent box, I agree to give Cycle Pharmaceuticals, its affiliates, subsidiaries, and business partners permission to use and disclose the personal information provided in this registration form, as described in this authorization. I authorize Cycle Pharmaceuticals and its service providers to contact me regarding Cycle Pharmaceuticals’ products, services, and programs via email, text, or phone (including using an automatic dialing system) based on the communication methods I have selected.

All personal information will be processed by or on behalf of Cycle Pharmaceuticals to deliver relevant marketing communications. Cycle Pharmaceuticals will retain personal information only for as long as it is required to complete the purposes for which it was collected and to fulfill its legal, regulatory and reporting obligations.

I understand that the information I am providing may be used by Cycle Pharmaceuticals to provide me with health and product information and related services concerning health conditions and treatments, and that Cycle Pharmaceuticals will treat my information in accordance with its Privacy Policy. I acknowledge that I am submitting this form voluntarily, and that I am at least 18 years of age. I understand I can opt out of receiving communications from Cycle Pharmaceuticals at any time by emailing marketing@cyclepharma.com.

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

Disclaimer: This discussion will reflect the clinical experience of Vanderbilt University and a private MS practice. Due to the specific patient cohorts observed, the results regarding the impact of switching between fumarates are not fully generalizable to all MS patient populations or diverse clinical settings. In determining the propriety of any treatment plan, clinicians should consider their professional judgment and the needs, preferences, and specific clinical circumstances of the individual patient. Further research with clinical trials is required to investigate these outcomes.

This webinar is intended for healthcare professionals (HCPs) involved in the management and treatment of patients with multiple sclerosis.

This educational webinar is sponsored and hosted by Cycle Pharmaceuticals, and the speakers have been compensated for their time.

This is a non‑promotional webinar.